Oncology News Central (ONC)New Frontline Standard or Not? Triple-Negative Breast Cancer Data Spark Debate

⚠️ Small Study / Early Comparative Evidence

The phase 3 ASCENT-04/KEYNOTE-D19 trial (n=443) previously demonstrated statistically significant PFS improvement for sacituzumab govitecan plus pembrolizumab over chemotherapy plus pembrolizumab in previously untreated PD-L1-positive advanced TNBC. At ASCO 2026, updated data focused on PFS2 given immature OS; PFS2 was not reached in the SG arm versus a median 21 months in the chemotherapy arm (HR 0.67; 95% CI 0.48–0.95), with 77% crossover from chemotherapy to SG after progression.

Clinical Considerations

• PFS2 favored frontline SG across the trial, with 24-month PFS2 rates of 63.7% vs 45.6% for SG and chemotherapy arms respectively, even with near-universal crossover to SG in the control arm
• An independent Dana-Farber/Harvard statistician characterized PFS2 as a “dubious outcome measure” with unclear endpoint definition that does not isolate whether frontline versus later-line use of the experimental therapy drives benefit
• FDA guidance does not recognize PFS2 as a meaningful contribution to benefit-risk assessment; EMA guidance assigns it only a supportive role when OS is infeasible as a secondary endpoint
• Median time to first subsequent therapy was 17.3 months in the SG arm vs 9.8 months in the chemotherapy arm (HR 0.59), a clearer and more interpretable finding than PFS2 per the independent reviewer

Practice Applications

• Recognize that frontline SG plus pembrolizumab demonstrates durable disease control signals, but OS data remain immature and standard-of-care designation is premature pending those results
• Interpret PFS2 findings in the context of high crossover rates; the control arm’s access to second-line SG substantially narrows the survival gap this endpoint can detect
• Monitor OS readout from ASCENT-04 as the definitive data point for frontline positioning of this regimen
• Consider industry funding and presenter financial disclosures when weighing enthusiasm for practice change based on this presentation